Mixture of carboxylic acids for treating patients with kidney failure

Abstract

A mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any possible combinations thereof. This product is used orally or also intravenously, in the treatment of patients with chronic renal failure, hyperammonemia or human conditions having negative nitrogen balance. This product is beneficial in decreasing the serum values of urea and serum ammonium, while promoting by transamination of the oxalacetate formed via succinate, fumarate and malate, the biosynthesis of non-essential amino acids; by transamination of the alpha ketoglutarate formed via citrate, it generates glutamic acid and related amino acids such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays deterioration of renal function and the urgent need for renal replacement therapy. In others, it is used as a supplemental renal replacement treatment to improve the patient's quality of life and improve laboratory parameters.

1 . A method of reducing uremia and hyperphosphatemia in patients with chronic renal failure, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising citric acid, succinic acid, fumaric acid, and malic acid, in combination with sodium bicarbonate, calcium carbonate and calcium lactate. 
     
     
         2 . The method according to  claim 1 , wherein the therapeutically effective amount of the composition administers to said patient is 12 to 1800 millimoles (2.304 grams to 345.6 grams) of citric acid per day. 
     
     
         3 . The method according to  claim 1 , wherein the therapeutically effective amount of the composition administers to said patient is 10 to 1800 millimoles (1.18 grams to 212.4 grams) of succinic acid per day. 
     
     
         4 . The method according to  claim 1 , wherein the therapeutically effective amount of the composition administers to said patient is 10 to 1800 millimoles (1.16 grams to 208.8 grams) of fumaric acid per day. 
     
     
         5 . The method according to  claim 1 , wherein the therapeutically effective amount of the composition administers to said patient is 10 to 1800 millimoles (1.34 grams to 241 grams) of malic acid per day. 
     
     
         6 . The method according to  claim 1 , wherein the composition is formulated: (i) as a powder to be reconstituted in drinking water or fruit juice; (ii) as effervescent tablets; or (iii) to be premixed or pre-constituted in fruit juices or ingestible drinks. 
     
     
         7 . The method according to  claim 1 , wherein the composition further comprises vitamin C, folic acid, ferrous sulfate, B complex and/or calcitriol. 
     
     
         8 . The method according to  claim 1 , wherein the composition further comprises artificial sweeteners of acesulfame, aspartame and/or sucralose. 
     
     
         9 . The method according to  claim 1 , wherein the composition further comprises monosaccharides of fructose and/or glucose; disaccharides of sucrose and/or lactose; and/or oligosaccharides of inulin and/or maguey honey. 
     
     
         10 . The method according to  claim 1 , wherein the composition further comprises taurine and/or L carnitine.